159 related articles for article (PubMed ID: 21703197)
1. c-Met activation through a novel pathway involving osteopontin mediates oncogenesis by the transcription factor LSF.
Yoo BK; Gredler R; Chen D; Santhekadur PK; Fisher PB; Sarkar D
J Hepatol; 2011 Dec; 55(6):1317-24. PubMed ID: 21703197
[TBL] [Abstract][Full Text] [Related]
2. Transcription factor Late SV40 Factor (LSF) functions as an oncogene in hepatocellular carcinoma.
Yoo BK; Emdad L; Gredler R; Fuller C; Dumur CI; Jones KH; Jackson-Cook C; Su ZZ; Chen D; Saxena UH; Hansen U; Fisher PB; Sarkar D
Proc Natl Acad Sci U S A; 2010 May; 107(18):8357-62. PubMed ID: 20404171
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner.
Phillips RJ; Helbig KJ; Van der Hoek KH; Seth D; Beard MR
World J Gastroenterol; 2012 Jul; 18(26):3389-99. PubMed ID: 22807608
[TBL] [Abstract][Full Text] [Related]
4. The transcription factor LSF: a novel oncogene for hepatocellular carcinoma.
Santhekadur PK; Rajasekaran D; Siddiq A; Gredler R; Chen D; Schaus SE; Hansen U; Fisher PB; Sarkar D
Am J Cancer Res; 2012; 2(3):269-85. PubMed ID: 22679558
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44+ cancer stem cells to 5 azacytidine in hepatocellular carcinoma.
Gao X; Sheng Y; Yang J; Wang C; Zhang R; Zhu Y; Zhang Z; Zhang K; Yan S; Sun H; Wei J; Wang X; Yu X; Zhang Y; Luo Q; Zheng Y; Qiao P; Zhao Y; Dong Q; Qin L
J Exp Clin Cancer Res; 2018 Jul; 37(1):179. PubMed ID: 30064482
[TBL] [Abstract][Full Text] [Related]
6. Small molecule inhibitors of Late SV40 Factor (LSF) abrogate hepatocellular carcinoma (HCC): Evaluation using an endogenous HCC model.
Rajasekaran D; Siddiq A; Willoughby JL; Biagi JM; Christadore LM; Yunes SA; Gredler R; Jariwala N; Robertson CL; Akiel MA; Shen XN; Subler MA; Windle JJ; Schaus SE; Fisher PB; Hansen U; Sarkar D
Oncotarget; 2015 Sep; 6(28):26266-77. PubMed ID: 26313006
[TBL] [Abstract][Full Text] [Related]
7. Late SV40 factor (LSF) enhances angiogenesis by transcriptionally up-regulating matrix metalloproteinase-9 (MMP-9).
Santhekadur PK; Gredler R; Chen D; Siddiq A; Shen XN; Das SK; Emdad L; Fisher PB; Sarkar D
J Biol Chem; 2012 Jan; 287(5):3425-32. PubMed ID: 22167195
[TBL] [Abstract][Full Text] [Related]
8. Thirty-kilodalton Tat-interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma.
Zhao J; Lu B; Xu H; Tong X; Wu G; Zhang X; Liang A; Cong W; Dai J; Wang H; Wu M; Guo Y
Hepatology; 2008 Jul; 48(1):265-75. PubMed ID: 18537194
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative small-molecule inhibitors of transcription factor LSF reveal oncogene addiction to LSF in hepatocellular carcinoma.
Grant TJ; Bishop JA; Christadore LM; Barot G; Chin HG; Woodson S; Kavouris J; Siddiq A; Gredler R; Shen XN; Sherman J; Meehan T; Fitzgerald K; Pradhan S; Briggs LA; Andrews WH; Sarkar D; Schaus SE; Hansen U
Proc Natl Acad Sci U S A; 2012 Mar; 109(12):4503-8. PubMed ID: 22396589
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of hepatitis C virus (HCV)-induced osteopontin and its role in epithelial to mesenchymal transition of hepatocytes.
Iqbal J; McRae S; Banaudha K; Mai T; Waris G
J Biol Chem; 2013 Dec; 288(52):36994-7009. PubMed ID: 24240095
[TBL] [Abstract][Full Text] [Related]
11. C-C chemokine receptor type 1 mediates osteopontin-promoted metastasis in hepatocellular carcinoma.
Zhu Y; Gao XM; Yang J; Xu D; Zhang Y; Lu M; Zhang Z; Sheng YY; Li JH; Yu XX; Zheng Y; Dong QZ; Qin LX
Cancer Sci; 2018 Mar; 109(3):710-723. PubMed ID: 29285854
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin Regulates Hepatitis C Virus (HCV) Replication and Assembly by Interacting with HCV Proteins and Lipid Droplets and by Binding to Receptors αVβ3 and CD44.
Iqbal J; Sarkar-Dutta M; McRae S; Ramachandran A; Kumar B; Waris G
J Virol; 2018 Jul; 92(13):. PubMed ID: 29669827
[TBL] [Abstract][Full Text] [Related]
13. Late SV40 factor: a key mediator of Notch signaling in human hepatocarcinogenesis.
Fan RH; Li J; Wu N; Chen PS
World J Gastroenterol; 2011 Aug; 17(29):3420-30. PubMed ID: 21876634
[TBL] [Abstract][Full Text] [Related]
14. Selenium sulfide disrupts the PLAGL2/C-MET/STAT3-induced resistance against mitochondrial apoptosis in hepatocellular carcinoma.
Yang T; Huo J; Xu R; Su Q; Tang W; Zhang D; Zhu M; Zhan Y; Dai B; Zhang Y
Clin Transl Med; 2021 Sep; 11(9):e536. PubMed ID: 34586726
[TBL] [Abstract][Full Text] [Related]
15. Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin.
Dong Q; Zhu X; Dai C; Zhang X; Gao X; Wei J; Sheng Y; Zheng Y; Yu J; Xie L; Qin Y; Qiao P; Zhou C; Yu X; Jia H; Ren N; Zhou H; Ye Q; Qin L
Oncotarget; 2016 Mar; 7(11):12997-3012. PubMed ID: 26824421
[TBL] [Abstract][Full Text] [Related]
16. Higher Matrix Stiffness Upregulates Osteopontin Expression in Hepatocellular Carcinoma Cells Mediated by Integrin β1/GSK3β/β-Catenin Signaling Pathway.
You Y; Zheng Q; Dong Y; Wang Y; Zhang L; Xue T; Xie X; Hu C; Wang Z; Chen R; Wang Y; Cui J; Ren Z
PLoS One; 2015; 10(8):e0134243. PubMed ID: 26280346
[TBL] [Abstract][Full Text] [Related]
17. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway.
Cao L; Fan X; Jing W; Liang Y; Chen R; Liu Y; Zhu M; Jia R; Wang H; Zhang X; Zhang Y; Zhou X; Zhao J; Guo Y
Oncotarget; 2015 Mar; 6(9):6627-40. PubMed ID: 25749383
[TBL] [Abstract][Full Text] [Related]
18. SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET.
He Q; Lin Z; Wang Z; Huang W; Tian D; Liu M; Xia L
Oncogene; 2020 Dec; 39(50):7279-7295. PubMed ID: 33046796
[TBL] [Abstract][Full Text] [Related]
19. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma.
Sun BS; Dong QZ; Ye QH; Sun HJ; Jia HL; Zhu XQ; Liu DY; Chen J; Xue Q; Zhou HJ; Ren N; Qin LX
Hepatology; 2008 Dec; 48(6):1834-42. PubMed ID: 18972404
[TBL] [Abstract][Full Text] [Related]
20. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
Steinway SN; Dang H; You H; Rountree CB; Ding W
PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
